Azacyclotritriacontane

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Azacyclotritriacontane
• 英文别名: azacyclotritriacontane
• 化学式: C₃₂H₆₅N
• 分子量: 463.9
• InChiKey: GJAUOJSKUNWWPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  15.1
• 重原子数：
  33
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] SALTS OF SCY-635 AND USES THEREOF IN MEDICINE<br/>[FR] SELS DE SCY-635 ET LEURS UTILISATIONS EN MÉDECINE
  申请人：WATERSTONE PHARMACEUTICALS WUHAN CO LTD

  公开号：WO2020118715A1

  公开（公告）日：2020-06-18

  The present invention relates to salts of a compound of formula (I) and uses thereof in medicine. Specifically, it relates to acid addition salt of compound of formula (I) and pharmaceutically compositions thereof. Furthermore, the invention relates to the uses of acid addition salt herein and pharmaceutically compositions thereof disclosed herein in the manufacture of a medicament, especially in the manufacture of a medicament for preventing, managing, treating or lessening hepatitis C virus (HCV) infection. (I)

  本发明涉及公式（I）化合物的盐及其在医学中的用途。具体而言，涉及公式（I）化合物的酸加盐及其药用组合物。此外，该发明还涉及酸加盐在此处的用途以及在本文中披露的药用组合物在制造药物中的用途，特别是在预防、管理、治疗或减轻丙型肝炎病毒（HCV）感染的药物制造中的用途。
• [EN] CRYSTALLINE FORM OF COMPOUND AND USES THEREOF IN MEDICINE<br/>[FR] FORME CRISTALLINE DE COMPOSÉ ET SES UTILISATIONS EN MÉDECINE
  申请人：WATERSTONE PHARMACEUTICALS WUHAN CO LTD

  公开号：WO2020038426A1

  公开（公告）日：2020-02-27

  A crystalline form A of the compound having formula (I) and uses thereof in medicine are described. Specifically, it relates to crystalline form A and pharmaceutically compositions thereof. Furthermore, it relates to the uses of crystalline form A disclosed herein and pharmaceutically compositions thereof disclosed herein in the manufacture of a medicament, especially in the manufacture of a medicament for preventing, managing, treating or lessening hepatitis C virus (HCV) infection.

  描述了化合物具有化学式(I)的晶体形式A及其在医学上的用途。具体而言，涉及晶体形式A及其药学组合物。此外，涉及本文所披露的晶体形式A的用途以及本文所披露的药学组合物在制造药物方面的用途，特别是在制造用于预防、管理、治疗或减轻丙型肝炎病毒（HCV）感染的药物方面。
• CRYSTALLINE FORM OF COMPOUND AND USES THEREOF IN MEDICINE
  申请人：Waterstone Pharmaceuticals (Wuhan) Co., Ltd.

  公开号：EP3841092A1

  公开（公告）日：2021-06-30
• MALEATE OF SCY-635 AND USES THEREOF IN MEDICINE
  申请人：Waterstone Pharmaceuticals (Wuhan) Co., Ltd.

  公开号：EP3893914A1

  公开（公告）日：2021-10-20
• [EN] CRYSTALLINE FORM OF COMPOUND AND USES THEREOF IN MEDICINE<br/>[FR] FORME CRISTALLINE D'UN COMPOSÉ ET SES UTILISATIONS EN MÉDECINE
  申请人：WATERSTONE PHARMACEUTICALS WUHAN CO LTD

  公开号：WO2020037530A1

  公开（公告）日：2020-02-27

  A crystalline form A of the compound having formula (I) and uses thereof in medicine are described. Specifically, it relates to crystalline form A and pharmaceutically compositions thereof. Furthermore, it relates to the uses of crystalline form A disclosed herein and pharmaceutically compositions thereof disclosed herein in the manufacture of a medicament, especially in the manufacture of a medicament for preventing, managing, treating or lessening hepatitis C virus (HCV) infection.